AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6%
Tue, 15 Sep

AUROBINDO PHARMA has announced its results for the quarter ended June 2020. Here is a detailed performance review of the same:

AUROBINDO PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Jun-19*
3
Mar-20*
3
Jun-20*
QoQ ChangeYoY Change
Net SalesRs m54,44661,58459,248-3.8%8.8%
Other incomeRs m1583261,156254.7%632.5%
TurnoverRs m54,60461,91060,404-2.4%10.6%
ExpensesRs m42,98248,42246,674-3.6%8.6%
Gross profitRs m11,33713,28512,574-5.4%10.9%
DepreciationRs m2,4092,3242,5559.9%6.1%
InterestRs m499318211-33.8%-57.8%
Profit before taxRs m8,58710,96810,9640.0%27.7%
TaxRs m2,2782,2853,03732.9%33.3%
Profit after taxRs m6,3108,6837,927-8.7%25.6%
Gross profit margin%20.821.621.2
Effective tax rate%26.520.827.7
Net profit margin%11.614.013.1
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 8.8% on a year-on-year (YoY) basis. The expenses were up by 8.6% YoY during the same period.
  • The company's operating profit increased by 10.9% YoY during the quarter. Consequently, operating profit margins remained same and stood at 21.2% in 1QFY21.
  • Depreciation charges increased by 6.1% and finance costs declined by 57.8% YoY, respectively.
  • Other income increased by 632.5% YoY during the quarter.
  • Net profit for the quarter increased by 25.6% YoY. Net profit margins during the quarter increased from 11.6% in 1QFY20 to 13.1% in 1QFY21.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter fell 3.8% on a quarter-on-quarter (QoQ) basis. The expenses were down by 3.6% QoQ during the same period.
  • The company's operating profit declined by 5.4% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 21.2% in 1QFY21 as against 21.6% in 4QFY20.
  • Net profit for the quarter declined by 8.7% QoQ, while net profit margins declined from 14.0% in 4QFY20 to 13.1% in 1QFY21.

To see how AUROBINDO PHARMA has performed over the last eight quarters,please visit here.

FREE Event: Discover Your First Stock for a Potential Rs 7 Crore in Long-term Wealth

AUROBINDO PHARMA Share Price Performance

Over the last one year,AUROBINDO PHARMA share price has moved up from Rs 629.8 to Rs 806.0, registering a Gain of Rs 176.3 or around 28.0%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 19,162.7 (up 1.1%). Over the last one year it has moved up from 13,022.7 to 19,162.7, a gain of 6,140 points (up 47.1%).

Overall, the S&P BSE SENSEX is up 4.9% over the year.

Current Valuations

At the current price of Rs 806.0, the price to earnings (P/E) ratio of AUROBINDO PHARMA stands at 15.7 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.4 times.

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6%". Click here!

  

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


May 7, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ADCOCK INGRAM COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS